title: Infliximab vs adalimumab for Crohn's disease: perhaps too early to call it a tie.
authors.affiliation: IBD Center, Division of Gastroenterology, Washington University in St Louis, St Louis, Missouri.
authors.forename: Themistocles
authors.initials: T
authors.lastname: Dassopoulos
authors.affiliation: IBD Center, Division of Gastroenterology, Virginia Tech-Carilion School of Medicine, Roanoke, Virginia; Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Sorrentino
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007155:Immunologic Factors